Dr. Hönle (HNL) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
7 Apr, 2026Historical milestones and market presence
Over 50 years of UV technology expertise, with roots dating back to 1976 and an IPO in 2001.
More than 8,000 investors and a global presence with over 20 locations.
Market leader in industrial UV technology, serving seven primary end markets.
Integrated group of eight brands under one umbrella, offering comprehensive UV solutions.
Technology and product portfolio
Core technologies include UV lamps/equipment and UV-curable adhesives.
Three main business units: Adhesive Systems, Curing, and Disinfection.
UV technology enables faster production, lower energy use, and environmentally friendly disinfection.
Product applications span electronics, automotive, optics, medical, food, printing, and environmental sectors.
Business unit highlights
Adhesive Systems focuses on electronics, medical, and automotive, with strong growth expected and expansion in China and the USA.
Curing unit targets packaging printing, coatings, and labels, with new LED-based solutions and cost reduction measures.
Disinfection unit offers a full range of log reduction for surface disinfection and unique microbiological analysis services.
Latest events from Dr. Hönle
- Stable revenue, weak Curing, strong Disinfection; full-year guidance and uncertainty persist.HNL
Q1 202613 Apr 2026 - EBITDA nearly doubled despite lower revenue, driven by cost controls and segment focus.HNL
Q4 202529 Jan 2026 - Curing and disinfection growth offset adhesives weakness; FY 2024/25 revenue guided at €92–94m.HNL
Company Presentation15 Sep 2025 - Revenue fell 9.6% year-over-year, but losses narrowed and full-year profit is expected.HNL
Q3 202415 Sep 2025 - Revenue fell 7.2% to €98.7m; restructuring and cost controls target future profitability.HNL
Q4 202415 Sep 2025 - EBITDA surged 69% despite a 10% revenue drop, with improved outlook for FY 2024/25.HNL
Q1 202515 Sep 2025 - EBITDA up 14% and EBIT positive despite 2% revenue drop, driven by cost savings and restructuring.HNL
Q2 202515 Sep 2025 - Revenue down 3.1% and net loss widened, but Disinfection unit delivered strong growth.HNL
Q3 202515 Sep 2025